Dr. Muneer M Abidi
Address: 1 Ford Pace, Detroit, Michigan, 48202, United States, Wayne State University
About the Doctor / Professional
I have been affiliated with the Division of Stem Cell Transplant and Cellular Therapy Program – Henry Ford Health System since April 2020. Previously, I worked in similar positions at Spectrum Health Cancer Center, Grand Rapids, MI for 6 years and Karmanos Cancer Center/ Wayne State University, Detroit, MI for approximately thirteen years. The Stem Cell Transplant and Cellular Therapy Program uses a comprehensive, multidisciplinary team approach to evaluate and treat patients who are candidates for bone marrow or peripheral blood stem cell transplant. As a Program Director I provide the quality and regulatory oversight. My primary research interest is in developing innovative treatment and supportive strategies for patients undergoing Stem cell transplant. I have been involved as a principal investigator in numerous investigator-initiated, pharmaceutical and cooperative group studies. I have been very actively involved in the Southwestern Oncology Group, Myeloma Committee and was coordinator of a National Clinical Trial, that determined one of the standards of care option for myeloma patients.
Contribution to Science
I have been actively involved in clinical research since 2001. My research interest is focused on designing clinical trials with innovative treatment strategies and supportive care for patients undergoing bone marrow transplant. I have extensively published on these topics in leading medical peer reviewed journal. In addition, I have also presented my scientific work at national and International conferences. I have been actively involved in SWOG myeloma committee since 2003 and have been coordinator of four national myeloma studies. One of these trials was published in Lancet and would change the standard of care. I have also assisted in examining new mobilization strategies for patients undergoing autologous stem cell transplant. My previous work in this field has increased understanding in the use of proteasome inhibitors and demonstrates the need for further work in this important area.
I have received funding for investigator-initiated studies for multiple trials during my career at Wayne State University/Karmanos Cancer Center. I always had one of the highest accrual in the pharmaceutical studies and completed trials successfully after initiation. Recently we had the third highest accrual in a pharmaceutical study at Spectrum Health which was completed in record time.
View Contact Details
Degree: The Aga Khan University Medical College Pakistan 1992
Residency: Washington University School of Medicine, St. Louis, Missouri, USA, 2001
- Previous Hospital Appointments:
- 2008-2014: Medical Director, Hematopoietic Stem Cell, Laboratory, Karmanos Cancer Institute, Detroit, MI
- 2008-2011: Medical Director, Marrow and Stem Cell Collection, Facility, Karmanos Cancer Institute, Detroit, MI
- 2003-2008: Director, Hematopoietic Stem Cell Laboratory, Karmanos Cancer Institute, Detroit, MI
- 2003-2011: Director, Marrow and Stem Cell Collection Facility, Karmanos Cancer Institute, Detroit, MI
- APPNA Pioneers Award
- Observational Study of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Multiday Highly Emetogenic Chemotherapy (HEC) Regimens for Hematological Malignancies.
- Biovitrum (Amgen) #200613161 Phase I/II Dose Escalation Trial of High Dose Melphalan Conditioning Regimen with Palifermin for Cyto-protection Followed by Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma.
- A randomized, double-blind, placebocontrolled Phase 3 study of SGN-35 (brentuximab vedotin) and best supportive care (BSC) versus placebo and BSC in the treatment of patients at high risk of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT).
- An Open-Label, Phase 2/3, Treatment-Option Protocol of Brentuximab Vedotin in Patients with Progression of Hodgkin Lymphoma.
- A Trial of Single Autologous Transplant Without or Without Consolidation Therapy Versus Tandem Autologous Transplant With Lenalidomide Maintenance for Patients with Multiple Myeloma.
- Millennium Pharmaceuticals: X05377: A Pilot Study of Peripheral Blood Hematopoietic Stem Cell Mobilization with the Combination of Bortezomib and G-CSF in Multiple Myeloma and NonHodgkin’s Lymphoma Patients.
- A Phase III Randomized, Multicenter Study comparing G-CSF Mobilized Peripheral Blood Stem Cell with Marrow Transplantation from HLC Compatible Unrelated Donors.
- A Multicenter Study of Hematopoietic Stem Cell Donor Safety and Quality of Life
- A pilot study of peripheral blood hematopoietic stem cells mobilization with the combination of bortezomib
- and G-CSF in multiple myeloma and non-hodgkin’s lymphoma patients, Blood,
- Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant.
- Evaluating the effects of lenalidomide induction therapy on
- peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple
- American Society of Hematology
- American Society for Transplantation and Cellular Therapy
- Southwest Oncology Group
- European Society for Blood and Marrow Transplantation
- Cell Therapy Transplant Canada